POMC and hyperinsulinemic hypoglycemia, familial, 4: It is also approved for use in patients with biallelic proopiomelanocortin (POMC) deficiency (including PCSK1) or biallelic leptin receptor (LEPR) deficiency caused by loss-of-function variants.